Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

LDL-C a poor predictor of recurrent cardiovascular disease in MI survivors

12 Oct 2019
Stem cells have been found to be responsible for calcification in arteries of patients with chronic kidney disease

Low-density lipoprotein cholesterol (LDL-C) levels after myocardial infarction (MI) have little value in identifying patients at high risk of recurrent atherosclerotic cardiovascular disease (rASCVD), a recent study has shown.

The study included 25,643 patients (median age, 63.3 years; 27 percent female) who survived their first-ever MI attack and were attending hospital revisits. The correlation between concentrations of lipid biomarkers, such as LDL-C, high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC), with the risk of rASCVD was assessed.

Over a median follow-up of 4.1 years, there were 2,173 cases of rASCVD, resulting in an overall incidence rate of 8.5 percent. No clear patterns of recurrence could be discerned when analysis was performed according to quintiles of LDL-C.

In contrast, rASCVD rates reliably increased according to categories of triglycerides, increasing from 17.6 event per 1,000 person-years in the bottom quintile to 24.1 events per 1,000 person-years at the top. Risk, as quantified by Cox proportional hazards models, scaled similarly across the triglyceride categories.

“Our data question the importance of LDL-C levels achieved at the first revisit post-MI for identifying high-risk patients and for decisions on continued treatment intensity,” said researchers.

“The incremental predictive value of LDL-C was minor when assessed together with other cardiovascular risk factors,” they added. “LDL-C was not superior to levels of TC, HDL-C or triglycerides for risk assessment in this nationwide cohort of first ever MI patients.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.